57th ASH Annual Meeting and Exposition (December 5-8, 2015): 605. Molecular Pharmacology, Drug Resistance – Lymphoid and Other Diseases: Novel Targets and Therapeutics

Molecular Pharmacology, Drug Resistance – Lymphoid and Other Diseases Oral and Poster Abstracts
Oral

W304EFGH, Level 3 (Orange County Convention Center)

Moderators:

Jennifer A. Woyach, MD, The Ohio State University and Birgit Knoechel, MD PhD, Dana Farber Cancer Institute

Disclosures:

No relevant conflicts of interest to declare.

4:30 PM

313

Ibrutinib Inhibits Both B-Cell Receptor and Toll-like Receptor Signaling in Chronic Lymphocytic Leukemia

Sarah E. M. Herman, PhD¹^*, Erin M. McAuley, BS¹, Deanna H. Wong, BS¹^*, Clare Sun, MD¹, Delong Liu, PhD²^* and Adrian Wiestner, MD, PhD¹

¹Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
²National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD

4:45 PM

314

FOXO1 Activation Is an Effector of SYK and AKT Inhibition in Tonic BCR Signal-Dependent Diffuse Large B-Cell Lymphomas

Przemyslaw Kiliszek, MSc¹^*, Maciej Szydlowski, PhD¹^*, Tomasz Sewastianik, MSc¹^*, Ewa Jablonska, PhD¹^*, Emilia Bialopiotrowicz, PhD¹^*, Patryk Gorniak, PhD¹^*, Anna Polak, MSc¹^*, Sergiusz Markowicz, PhD²^*, Eliza Nowak, MSc²^*, Monika A. Grygorowicz, MSc²^*, Monika Prochorec-Sobieszek, MD, PhD¹^*, Anna Szumera-Cieckiewicz, MD, PhD¹^*, Agata Malenda, MD, PhD³^*, Ewa Lech-Maranda, MD, PhD^3,4^*, Krzysztof Warzocha, MD, PhD³^* and Przemyslaw Juszczynski, MD, PhD¹

¹Dept. of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
²Dept. of Immunology, Maria Sklodowska-Curie Memorial Cancer Center – Institute of Oncology, Warsaw, Poland
³Dept. of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
⁴Centre of Postgraduate Medical Education, Institute of Hematology and Transfusion Medicine, Warsaw, Poland

5:00 PM

315

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc¹^*, Shady Adnan, MD, MSc²^*, Leopold Sellner, MD³^*, Dorine Bellanger⁴^*, Alexandra Schrader⁵^*, Giuliano Crispatzu⁵^*, Henan Zhang, MD⁶, Carlos C Mateos, PhD⁷^*, Edgar Faber, MD, PhD⁸^*, Steffen Koschmieder, MD⁹, Tim H. Brummendorf, MD, PhD⁹, Krister Wennerberg, PhD¹⁰^*, Wei Ding, MD, PhD⁶, Marc-Henri Stern, MD, PhD⁴^*, Marco Herling, MD⁵^*, Simon Anders, PhD¹⁰^*, Wolfgang Huber, PhD¹¹^*, Thorsten Zenz, MD³^* and Satu Mustjoki, M.D., PhD.²

¹Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
²Department of Hematology, Comprehensive Cancer Center, Hematology Research Unit Helsinki (HRUH), Helsinki, Finland
³NCT/DKFZ Heidelberg, Heidelberg, Germany
⁴Institut Curie, Paris, France
⁵CECAD and Dept. of Medicine I Cologne University, Cologne, Germany
⁶Hematology/Oncology division, Mayo Clinic, Rochester, MN
⁷Departamento de Immunología, Hospital Universitario de la Princesa, Madrid, Spain
⁸Department of Hemato-oncology, University Hospital Olomouc, Olomouc, Czech Republic
⁹RWTH Aachen University Hospital, Aachen, Germany
¹⁰FIMM, Helsinki, Finland
¹¹European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany

5:15 PM

316

Mobilization of Human Immature Hematopoietic Progenitors after Combinatory Use of Bortezomib and Immunomodulatory Drugs

Taro Tochigi¹^*, Takatoshi Aoki, MD²^*, Yoshikane Kikushige, MD, PhD¹^*, Tomohiko Kamimura, MD, PhD²^*, Takuji Yamauchi, MD, PhD¹^*, Koji Kato, MD, PhD¹, Katsuto Takenaka, MD, PhD³^*, Toshihiro Miyamoto, MD, PhD³ and Koichi Akashi, MD, PhD¹

¹Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
²Department of Hematology, Harasanshin Hospital, Fukuoka, Japan
³Kyushu University Hospital, Fukuoka, Japan

5:30 PM

317

Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies

Zachary A. Hing, BS^1,2, Ho Yee Joyce Fung, BA³^*, Parvathi Ranganathan, PhD⁴^*, Shaneice Mitchell, BS²^*, Dalia El-Gamal, PhD², Jennifer A. Woyach, MD², Katie Williams, MS²^*, Virginia M. Goettl, DVM , PhD²^*, Jordan L. Smith, BS⁴^*, Xueyan Yu⁴^*, Xiaomei Meng⁴^*, Qingxiang Sun, PhD³^*, Tolga Cagatay, PhD³^*, John B. MacMillan, PhD⁵^*, Amy M. Lehman, MAS⁶^*, David M. Lucas, PhD², Erkan Baloglu, PhD⁷^*, Sharon Shacham⁷^*, Michael Kauffman, MD, PhD⁷, John C. Byrd, MD^2,8, Yuh Min Chook, PhD³^*, Ramiro Garzon, MD⁴ and Rosa Lapalombella, PhD²

¹Medical Scientist Training Program, The Ohio State University, Columbus, OH
²Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
³Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX
⁴The Comprehensive Cancer Center, The Ohio State University, Columbus, OH
⁵Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX
⁶Center for Biostatistics, Department of Bioinformatics, The Ohio State University, Columbus, OH
⁷Karyopharm Therapeutics, Inc, Newton, MA
⁸Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH

5:45 PM

318

A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and In Vitro Potency in B-Cell Malignancies

Dalia El-Gamal, PhD¹, Zachary A. Hing, BS¹, Shaneice Mitchell, BS¹^*, Taylor D. LaFollette¹^*, Paul J. Brennan¹^*, Joseph M. Flynn, DO, MPH¹, Jeffrey A. Jones, MD, MPH¹, Farrukh Awan, MD, MS¹, Leslie A. Andritsos, MD¹, James S. Blachly, MD¹, Katie Williams, MS¹^*, Bonnie K. Harrington, DVM²^*, Virginia M. Goettl, DVM , PhD¹^*, Jennifer A. Woyach, MD¹, Amy M. Lehman, MAS³^*, Lianbo Yu, PhD³^*, John C. Byrd, MD¹ and Rosa Lapalombella, PhD¹

¹Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
²College of Veterinary Medicine, The Ohio State University, Columbus, OH
³Center for Biostatistics, Department of Bioinformatics, The Ohio State University, Columbus, OH

See more of: Molecular Pharmacology, Drug Resistance – Lymphoid and Other Diseases
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

605.O2.6 605. Molecular Pharmacology, Drug Resistance – Lymphoid and Other Diseases: Novel Targets and Therapeutics